The DOI matches its Crossref record.
Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine
Open accessAbstract
The antibody kinetics in sera from 27 adults after three doses of the Norwegian group B meningococcal outer membrane vesicle (OMV) vaccine was studied. The vaccinees received the third dose 4 to 5 years after the first two. Antibody responses against outer membrane proteins (OMPs) and lipopolysaccharides were studied by enzyme-linked immunosorbent assay and immunoblotting and with serum bactericidal assays (SBA) with three variants of the vaccine strain, 44/76. Six weeks after the second injection, the geometric mean (GM) of the levels of immunoglobulin G (IgG) against OMVs was about sevenfold higher than that of prevaccination levels, and 74% of the vaccinees developed a greater-than-twofold rise in SBA titer. After 6 months, the GM of IgG levels declined to about threefold higher, and after 4 to 5 years it declined to about twofold higher, than that before vaccination. The third dose induced a rapid increase in SBA titers in 96% of the vaccinees, and the GM of levels of IgG against OMVs rose to about 14-fold the prevaccination level. One year later, the IgG antibody levels had dropped to 4.6-fold the prevaccination level, but 88% of the vaccinees still showed bactericidal activity. The response after the two first doses was higher in individuals with prevaccination antibodies, but no such effect was found after three doses. The use of defined mutants in SBA and linear multiple regression analyses indicated that among the major OMPs, antibodies to the Opc and class 1 proteins made the most important single contributions to the bactericidal activity against the vaccine strain, but it also demonstrated the importance of antibodies against other antigens. After three doses, 68% of the vaccinees showed a significant SBA response against a strain lacking both the Opc and the class 1 proteins. Three doses converted almost all subjects to SBA responders and gave higher antibody levels and relatively less serosubtype-specific bactericidal activity than did two doses, probably indicating a broader cross-protection against heterologous strains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Therapeutically harnessing extracellular vesicles
Cheng, L., & Hill, A. F. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00410-w · Cited by 737
Holst, J., Martin, D., Arnold, R., Huergo, C. C., Oster, P., O’Hallahan, J., & Rosenqvist, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.071 · Cited by 405
Self-citationTappero, J. W., Lagos, R., Maldonado Ballesteros, A., Plikaytis, B., Williams, D., Dykes, J., Gheesling, L. L., Carlone, G. M., Høiby, E. A., Holst, J., et al. (1999) · JAMA · doi:10.1001/jama.281.16.1520 · Cited by 369
Self-citationMannose-targeted systems for the delivery of therapeutics
Irache, J. M., Salman, H. H., Gamazo, C., & Espuelas, S. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.6.703 · Cited by 293
OSTER, P., LENNON, D., OHALLAHAN, J., MULHOLLAND, K., REID, S., & MARTIN, D. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.063 · Cited by 271
Metadata
- Authors
- Rosenqvist, E., Høiby, E. A., Wedege, E., Bryn, K., Kolberg, J., Klem, A., Rønnild, E., Bjune, G., & Nøkleby, H.
- Venue
- Infection and Immunity
- Publisher
- American Society for Microbiology
- Published
- 1995-12
- Volume
- 63
- Issue
- 12
- Pages
- 4642-4652
- ISSN
- 0019-9567 (ISSN-L)
- 1098-5522
- OpenAlex
- W2132306802
- Cited by
- 249
- References
- 0
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. https://app.cochat.ai/papers/10.1128/iai.63.12.4642-4652.1995
- The paper
- Rosenqvist, E., Høiby, E. A., Wedege, E., Bryn, K., Kolberg, J., Klem, A., Rønnild, E., Bjune, G., & Nøkleby, H. (1995). Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infection and Immunity. https://doi.org/10.1128/iai.63.12.4642-4652.1995
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.